Literature DB >> 9602185

Risk of hemolytic uremic syndrome after sporadic Escherichia coli O157:H7 infection: results of a Canadian collaborative study. Investigators of the Canadian Pediatric Kidney Disease Research Center.

P C Rowe1, E Orrbine, H Lior, G A Wells, E Yetisir, M Clulow, P N McLaine.   

Abstract

OBJECTIVES: The objectives of this study were to better estimate the age-specific risks of hemolytic uremic syndrome (HUS) and hemolytic anemia after Escherichia coli O157:H7 infection among a representative cohort of both referred and nonreferred children with documented illness from the province of Alberta and to compare this with the rates in children evaluated at referral centers in the rest of Canada. STUDY
DESIGN: Children with HUS or E. coli O157:H7 gastroenteritis were eligible if they were < 15 years of age. Hemoglobin, blood smear, urinalysis, and serum creatinine were obtained 8 to 10 days after the onset of diarrhea to ascertain for hemolysis, anemia, thrombocytopenia, and renal injury. Subjects were monitored for 1 month.
RESULTS: From June 1991 to March 1994, HUS was diagnosed in 205 children. Of these 77% had evidence of E. coli O157:H7 infection. A further 582 children had E. coli O157:H7 gastroenteritis, of whom 18 had hemolytic anemia. The risk of HUS after E. coli O157:H7 infection in Alberta was 8.1% (95% confidence interval, 5.3 to 11.6) compared with 31.4% in referral centers in the rest of Canada. In Alberta the highest age-specific risk of HUS/hemolytic anemia was 12.9% in those < 5 years of age.
CONCLUSIONS: These data will help guide clinical care and provide a basis for estimating the sample sizes required in future treatment trials for the secondary prevention of HUS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9602185     DOI: 10.1016/s0022-3476(98)70303-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  22 in total

1.  Haemolytic uraemic syndrome and E coli O157.

Authors:  M Fitzpatrick
Journal:  BMJ       Date:  1999-03-13

2.  Epidemiological characteristics of reported sporadic and outbreak cases of E. coli O157 in people from Alberta, Canada (2000-2002): methodological challenges of comparing clustered to unclustered data.

Authors:  D L Pearl; M Louie; L Chui; K Doré; K M Grimsrud; S W Martin; P Michel; L W Svenson; S A McEwen
Journal:  Epidemiol Infect       Date:  2007-06-13       Impact factor: 2.451

Review 3.  Chronic sequelae of E. coli O157: systematic review and meta-analysis of the proportion of E. coli O157 cases that develop chronic sequelae.

Authors:  Jessica Keithlin; Jan Sargeant; M Kate Thomas; Aamir Fazil
Journal:  Foodborne Pathog Dis       Date:  2013-11-27       Impact factor: 3.171

4.  The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.

Authors:  C S Wong; S Jelacic; R L Habeeb; S L Watkins; P I Tarr
Journal:  N Engl J Med       Date:  2000-06-29       Impact factor: 91.245

5.  Non-O157:H7 Shiga Toxin Producing Diarrhoeagenic Escherichia coli (STEC) in Southern India: A Tinderbox for Starting Epidemic.

Authors:  Shashank Purwar; Subrana Roy; Sharada Metgud
Journal:  J Clin Diagn Res       Date:  2016-10-01

6.  Predicting Hemolytic Uremic Syndrome and Renal Replacement Therapy in Shiga Toxin-producing Escherichia coli-infected Children.

Authors:  Ryan S McKee; David Schnadower; Phillip I Tarr; Jianling Xie; Yaron Finkelstein; Neil Desai; Roni D Lane; Kelly R Bergmann; Ron L Kaplan; Selena Hariharan; Andrea T Cruz; Daniel M Cohen; Andrew Dixon; Sriram Ramgopal; Annie Rominger; Elizabeth C Powell; Jennifer Kilgar; Kenneth A Michelson; Darcy Beer; Martin Bitzan; Christopher M Pruitt; Kenneth Yen; Garth D Meckler; Amy C Plint; Stuart Bradin; Thomas J Abramo; Serge Gouin; April J Kam; Abigail Schuh; Fran Balamuth; Tracy E Hunley; John T Kanegaye; Nicholas E Jones; Usha Avva; Robert Porter; Daniel M Fein; Jeffrey P Louie; Stephen B Freedman
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

7.  Prospective surveillance of Canadian children with the haemolytic uraemic syndrome.

Authors:  François Proulx; Paul Sockett
Journal:  Pediatr Nephrol       Date:  2005-04-15       Impact factor: 3.714

8.  Performance of the ImmunoCard STAT! E. coli O157:H7 test for detection of Escherichia coli O157:H7 in stools.

Authors:  A Mackenzie; E Orrbine; L Hyde; M Benoit; F Chan; C Park; J Alverson; A Lembke; D Hoban; W Kennedy
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

9.  Protective effect of Lactobacillus casei strain Shirota on Shiga toxin-producing Escherichia coli O157:H7 infection in infant rabbits.

Authors:  M Ogawa; K Shimizu; K Nomoto; M Takahashi; M Watanuki; R Tanaka; T Tanaka; T Hamabata; S Yamasaki; Y Takeda
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

10.  Shiga toxin 2 targets the murine renal collecting duct epithelium.

Authors:  Mitchell A Psotka; Fumiko Obata; Glynis L Kolling; Lisa K Gross; Moin A Saleem; Simon C Satchell; Peter W Mathieson; Tom G Obrig
Journal:  Infect Immun       Date:  2009-01-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.